Viking Therapeutics reports Q3 2026 loss, cash boost and advances obesity drug trials
Viking Therapeutics posted a net loss of $183.2 million, or $1.55 per share, for the third quarter of 2026. The company ended the quarter with $960 million in cash after raising about $575 million from upsized stock and convertible‑note offerings. It also announced the start of the SUNRISE Phase 3 oral VK2735 trial and continued enrollment in the VANQUISH Phase 3 subcutaneous trials, both expected to finish in 2027. A Phase 1 study of the amylin agonist VK3019 is nearing completion with a multiple‑ascending‑dose study planned for Q1 2027.
Why it matters
The widened loss reflects higher R&D and administrative spending, but the strong cash position gives the company runway to fund its late‑stage obesity programs (the company says the cash will support trial execution and commercial launch plans). Successful Phase 3 results could unlock a new obesity treatment and improve future revenue prospects.
Key facts
- 1Net loss for Q3 2026 was $183.2 million, or $1.55 per share. finance.yahoo.com
- 2Quarter‑end cash, cash equivalents and short‑term investments were $960 million. prnewswire.com
- 3The company raised gross proceeds of approximately $575 million from concurrent upsized offerings of common stock and convertible senior notes. finance.yahoo.com
- 4The SUNRISE Phase 3 program for oral VK2735 was initiated in Q3 2026. prnewswire.com
- 5VANQUISH Phase 3 trials for subcutaneous VK2735 continue to advance and are expected to be completed in 2027. prnewswire.com
- 6Phase 1 SAD study of VK3019 is nearing completion, with a 28‑day multiple‑ascending‑dose study planned for Q1 2027. prnewswire.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.